COVID-19 and Cancer Immunotherapy Research: Cancer Research Institute

CRI immunotherapy experts discuss some of the ways that research on the immune system and its response to cancer and infectious diseases has led to new lifesaving therapies for cancer patients and aiding global efforts to treat COVID-19 patients and prevent future outbreaks. #CIM20 #COVID19 The live stream event “COVID-19 and Cancer Immunotherapy Research: How Science from the Frontlines of Immuno-Oncology Is Helping Inform Strategies to Treat and Prevent COVID-19” featured CRI immunotherapy experts Drs. Carl H. June, Miriam Merad, and E. John Wherry (moderated by Matthew Herper, STAT) followed by audience Q&A.… Carl H. June, M.D., is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine, director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.… Miriam Merad, M.D., Ph.D., is the Mount Sinai Endowed Professor in Cancer Immunology and the director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai in New York.… E. John Wherry, Ph.D., is the Barbara and Richard Schiffrin President’s Distinguished Professor, chair of the Department of Systems Pharmacology and Translational Therapeutics in the Perelman School of Medicine and director of the UPenn Institute for Immunology.… This live stream event is part of the 8th Annual Cancer Immunotherapy Month™ in June 2020, hosted by the Cancer Research Institute. Help us raise awareness of the lifesaving potential of immunotherapy for all types of cancer. Let’s fuel the next scientific discoveries and breakthrough treatments through learning, engagement, and storytelling. #Immune2Cancer Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers.

About The Author